Stephen D. (Brigham and Women's Hospital) Wiviott,
S Wiviott
John Wiley & Sons
e druk, 2008
9781405176262
Antiplatelet Therapy In Ischemic Heart Disease
Specificaties
Gebonden, 312 blz.
|
Engels
John Wiley & Sons |
e druk, 2008
ISBN13: 9781405176262
Rubricering
Onderdeel van serie
American Heart Association Clinical Series
Levertijd ongeveer 8 werkdagen
Samenvatting
∗ Draws from expertise of leaders in antiplatelet therapy
∗ Easy–to–use layout enables rapid browsing
∗ Edited by a member of the prestigious TIMI study group with long–standing experience in the field
Specificaties
Inhoudsopgave
Part I Concepts in Platelet Physiology, Function and Measurement.
<p>1 Platelet physiology and the role of the platelet in ischemic heart disease.</p>
<p>Robert F. Storey .</p>
<p>2 Laboratory assessment of platelet function and the effects of antiplatelet agents.</p>
<p>Alan D. Michelson, A.L. Frelinger .</p>
<p>Part II Pharmacology of Oral Antiplatelet Agents.</p>
<p>3 Cyclooxygenase inhibitors.</p>
<p>Nina Chetty Raju, John W. Eikelboom .</p>
<p>4 Aspirin response variability and resistance.</p>
<p>Wai–Hong Chen, Daniel I. Simon .</p>
<p>5 P2Y12 inhibitors: Thienopyridines and direct oral inhibitors.</p>
<p>Jean–Philippe Collet, Boris Aleil, Christian Gachet, Gilles Montalescot .</p>
<p>6 Thienopyridine response variability and resistance.</p>
<p>Udaya S. Tantry, Thomas A. Suarez, Paul A. Gurbel .</p>
<p>Part III Pharmacology of Intravenous Antiplatelet Agents.</p>
<p>7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists.</p>
<p>James C. Blankenship, Peter B. Berger .</p>
<p>8 Intravenous P2Y12 inhibitors.</p>
<p>Steven P. Dunn, Steven R. Steinhubl .</p>
<p>9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents.</p>
<p>Nicolai Mejevoi, Anjum Tanwir, Marc Cohen .</p>
<p>Part IV Clinical Use of Antiplatelet Agents in Cardiovascular Disease.</p>
<p>10 Antiplatelet therapy in acute coronary syndrome with ST elevation.</p>
<p>Christian W. Hamm .</p>
<p>11 Antiplatelet therapy in ST–elevation myocardial infarction.</p>
<p>Michelle O′Donoghue, Marc S. Sabatine .</p>
<p>12 Antiplatelet therapy in chronic artery disease.</p>
<p>Kamran I. Muhammed, Deepak L. Bhatt .</p>
<p>13 Antiplatelet therapy in peripheral arterial disease.</p>
<p>Esther S. Kim, Heather L. Gornik .</p>
<p>14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases.</p>
<p>Larry B. Goldstein .</p>
<p>Part V Special Circumstances.</p>
<p>15 Antiplatelet therapy and coronary bypass surgery: risks and benefits.</p>
<p>A. Burdess, N.L. Cruden, K.A. Fox .</p>
<p>16 Management of antiplatelet therapy for non–cardiac surgery.</p>
<p>Nisheeth Goel, John F. Canales, James J. Ferguson .</p>
<p>17 Antiplatelet therapy and coronary stents.</p>
<p>Alanna Coolong, Laura Mauri</p>
<p>1 Platelet physiology and the role of the platelet in ischemic heart disease.</p>
<p>Robert F. Storey .</p>
<p>2 Laboratory assessment of platelet function and the effects of antiplatelet agents.</p>
<p>Alan D. Michelson, A.L. Frelinger .</p>
<p>Part II Pharmacology of Oral Antiplatelet Agents.</p>
<p>3 Cyclooxygenase inhibitors.</p>
<p>Nina Chetty Raju, John W. Eikelboom .</p>
<p>4 Aspirin response variability and resistance.</p>
<p>Wai–Hong Chen, Daniel I. Simon .</p>
<p>5 P2Y12 inhibitors: Thienopyridines and direct oral inhibitors.</p>
<p>Jean–Philippe Collet, Boris Aleil, Christian Gachet, Gilles Montalescot .</p>
<p>6 Thienopyridine response variability and resistance.</p>
<p>Udaya S. Tantry, Thomas A. Suarez, Paul A. Gurbel .</p>
<p>Part III Pharmacology of Intravenous Antiplatelet Agents.</p>
<p>7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists.</p>
<p>James C. Blankenship, Peter B. Berger .</p>
<p>8 Intravenous P2Y12 inhibitors.</p>
<p>Steven P. Dunn, Steven R. Steinhubl .</p>
<p>9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents.</p>
<p>Nicolai Mejevoi, Anjum Tanwir, Marc Cohen .</p>
<p>Part IV Clinical Use of Antiplatelet Agents in Cardiovascular Disease.</p>
<p>10 Antiplatelet therapy in acute coronary syndrome with ST elevation.</p>
<p>Christian W. Hamm .</p>
<p>11 Antiplatelet therapy in ST–elevation myocardial infarction.</p>
<p>Michelle O′Donoghue, Marc S. Sabatine .</p>
<p>12 Antiplatelet therapy in chronic artery disease.</p>
<p>Kamran I. Muhammed, Deepak L. Bhatt .</p>
<p>13 Antiplatelet therapy in peripheral arterial disease.</p>
<p>Esther S. Kim, Heather L. Gornik .</p>
<p>14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases.</p>
<p>Larry B. Goldstein .</p>
<p>Part V Special Circumstances.</p>
<p>15 Antiplatelet therapy and coronary bypass surgery: risks and benefits.</p>
<p>A. Burdess, N.L. Cruden, K.A. Fox .</p>
<p>16 Management of antiplatelet therapy for non–cardiac surgery.</p>
<p>Nisheeth Goel, John F. Canales, James J. Ferguson .</p>
<p>17 Antiplatelet therapy and coronary stents.</p>
<p>Alanna Coolong, Laura Mauri</p>